Emergence of orphan drugs in the United States: a quantitative assessment of the first 25 years
M. Miles Braun(Center for Biologics Evaluation and Research), Timothy R. Coté(Center for Biologics Evaluation and Research), Sheiren Farag-El-Massah(United States Food and Drug Administration), Kui Xu(City Of Hope National Medical Center)
Cited by 151
Related Papers
Tuberculosis Associated with Infliximab, a Tumor Necrosis Factor α–Neutralizing Agent
|New England Journal of Medicine|2001|3.7k
Tumor necrosis factor antagonist therapy and lymphoma development: Twenty‐six cases reported to the Food and Drug Administration
|Arthritis & Rheumatism|2002|661
Case Reports of Heart Failure after Therapy with a Tumor Necrosis Factor Antagonist
|Annals of Internal Medicine|2003|459
Life‐threatening histoplasmosis complicating immunotherapy with tumor necrosis factor α antagonists infliximab and etanercept
|Arthritis & Rheumatism|2002|448